Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000012

EU PAS number

EUPAS1000000012

Study ID

1000000012

Official title and acronym

id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe

DARWIN EU® study

No

Study countries

France
Germany
Italy
Spain
United Kingdom

Study description

id.DRIVE’s Study Network will be leveraged to continuously monitor severe acute respiratory infection (SARI)-causing pathogens (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza, and respiratory syncytial virus [RSV]), including virological and clinical trends, as well as burden of disease (e.g., pathogen-specific morbidity; in-hospital mortality).
The surveillance of additional pathogens allows for study preparedness, with the potential to perform feasibility assessments for future impact and effectiveness studies within the id.DRIVE Study Network.

Study status

Ongoing
Research institution and networks

Institutions

P95 Epidemiology & Pharmacovigilance
Belgium
Colombia
Netherlands
South Africa
Thailand
United States
First published:
09/04/2024
InstitutionLaboratory/Research/Testing facilityNon-Pharmaceutical companyENCePP partner
Imperial College London
United Kingdom
First published:
01/02/2024
InstitutionEducational Institution
Valencia Hospital Network for the Study of Influenza and Other Respiratory Viruses (VAHNSI)
Centro Interuniversitario per la Ricerca sull’Influenza e le altre Infezioni (CIRI-IT)
Germans Trias i Pujol University Hospital
Universitätsklinikum Ulm
Universitätsklinikum Frankfurt
Ospedale Luigi Sacco
Hospital Clínic de Barcelona
Hospital Clínico Universitario de Santiago de Compostela
Hospital Universitario La Paz
Hôpitaux Universitaires Henri-Mondor
Manchester University NHS Foundation Trust (MFT)
NHS Lothian

Networks

id.DRIVE (former COVIDRIVE)
Austria
Belgium
Croatia
Czechia
Denmark
France
Germany
Iceland
Italy
Poland
Romania
Spain
First published:
29/02/2024
Network
ENCePP partner

Contact details

Kaatje Bollaerts

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, Pfizer
Study protocol
Initial protocol

Surveillance study_Protocol_V1.0_21 Mar 2024.pdf

English (832.64 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable